Press Releases

AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no

Feb 09, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to

Feb 04, 2022

AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 1, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O’Bryan as chief regulatory officer.

Feb 01, 2022

AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 28, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO , will present

Jan 28, 2022

AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022 , at 8:00 a.m. ET Five platform presentations and three posters on the company’s clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.

Jan 27, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Jan 06, 2022

AVROBIO Reprioritizes Pipeline Programs

Fabry disease program to be deprioritized, shifting focus to other clinical-stage programs in lysosomal disorder pipeline Data updates for cystinosis and Gaucher disease type 1 programs planned for 1H 2022, with regulatory interactions anticipated across multiple programs in 2022 Cash runway to be

Jan 04, 2022



Displaying 11 - 17 of 17

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.